Nykode Therapeutics Investor Relations Material
Access more data
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies in the fields of cancer and infectious diseases. The company develops vaccines for the treatment cancer, melanoma, lung, head and neck, renal, bladder cancer; Nkyode Therapeutics AS was formerly known as Vaccibody AS. The Company's lead product candidates include VB10.NEO (Oncolytic Immunotherapy), which has completed Phase I/IIa clinical trial; it also has development collaboration agreements with Roche, Genentech and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; research agreement with Regeneron.
Key slides for Nykode Therapeutics
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023